TIP_link_300x300.jpg
Neoantigens Market Size ($10,54,783.54 Thousand by 2028) Growth Forecast at 31.2% CAGR During 2023 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
October 07, 2021 10:16 ET | The Insight Partners
New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Neoantigens Market: Key InsightsAccording to our new research study on “Neoantigens Market to 2028 – Global Analysis and Forecast – by Treatment and...
VAXIMM_LOGO_CMYK_300dpi.jpg
VAXIMM to Attend International Scientific and Industry Events
May 27, 2021 03:30 ET | VAXIMM AG
BASEL, Switzerland and MANNHEIM, Germany, May 27, 2021 (GLOBE NEWSWIRE) -- VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to...
VAXIMM, 다수의 해외 과학 및 산업 이벤트 참가 예정
May 27, 2021 03:30 ET | VAXIMM AG
스위스 바젤/독일 만하임, May 27, 2021 (GLOBE NEWSWIRE) -- 스위스/독일 바이오테크 회사인 VAXIMM AG가 다수의 해외 과학 및 산업 이벤트 참석 계획을 발표했다. 자사는 환자의 세포독성 T세포 활성화를 통해 다양한 암 관련 항원을 표적으로 하는 경구용 플러그 앤 플레이(plug and play) DNA 백신 투여 기술...
Aldevron announces GMP gene synthesis service to support neoantigen-based oncology research and other applications
October 02, 2019 11:10 ET | Aldevron
Fargo, ND, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require...
Achilles-Therapeutics-Logo-RGB-Small.png
Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma
February 13, 2019 03:00 ET | Achilles Therapeutics
   Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma Second CTA approval in 2019 – the first was for a NSCLC study Stevenage, UK  13 February...